Rozalyn Littler

Rozalyn has over 20 years of drug development regulatory affairs and quality experience working previously at Metacrine, Heron Therapeutics, Genentech, MedImmune, and Johnson and Johnson, as well as an independent consultant.  Rozalyn’s experience has spanned all stages of drug development from pre-investigational new drug (IND) activities through new drug  application (NDA) submission, Advisory Committee, and post-approval.  She has worked on products such as Avastin®, Sustol ®, and CINVANTI®.  Rozalyn earned her Bachelors of Science in Engineering, Radiation Health Physics, from Oregon State University.